Premium
Evaluation of C‐reactive protein, interleukin‐6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients
Author(s) -
Pihusch Markus,
Pihusch Rudolf,
Fraunberger Peter,
Pihusch Verena,
Andreesen Reinhard,
Kolb HansJochem,
Holler Ernst
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.0902-4441.2005.00568.x
Subject(s) - procalcitonin , medicine , gastroenterology , hematopoietic stem cell transplantation , c reactive protein , transplantation , immunology , sepsis , inflammation
Background: Prompt detection of transplant‐related complications (TRC) as infections, acute graft‐versus‐host disease (aGVHD), microangiopathic hemolytic anemia, or veno‐occlusive disease following allogeneic hematopoietic stem cell transplantation (HSCT) is essential. Patients and methods: We conducted a prospective trial on clinical significance of C‐reactive protein (CRP), interleukin‐6 (IL‐6) and procalcitonin (PCT) serum levels in TRC. A total of 350 stem cell recipients were admitted. CRP, IL‐6 and PCT were analyzed prior to conditioning and weekly until 8 wk after HSCT. TRC were recorded weekly throughout the study. Results: CRP (4.4 mg/dL vs. 12.8 mg/dL; P < 0.001), IL‐6 (93 ng/mL vs. 1.138 ng/mL; P < 0.001) and PCT (0.8 ng/dL vs. 5.7 ng/dL; P < 0.001) were increased in infectious complications. Only PCT differentiated between infection and other TRC. Exclusive aGVHD did not increase CRP (4.4 mg/dL vs. 5.7 mg/dL; n.s.), IL‐6 (93 ng/mL vs. 153 ng/mL; n.s.) and PCT (0.8 ng/dL vs. 0.8 ng/dL; n.s.). CRP (6.1 mg/dL vs. 3.1 mg/dL; P < 0.001) and IL‐6 (295 ng/mL vs. 122 ng/mL; P = 0.001) were decreased during steroid therapy, but not PCT (2.3 ng/dL vs. 2.0 ng/dL; n.s.). Conclusion: Our study confirmed CRP, IL‐6 and PCT serum levels as helpful markers for TRC. PCT can differentiate infection from GVHD despite steroid therapy. Further trials are needed focusing on the identification of patients who benefit from early risk stratification.